Physician profile
Stuart A Green
NPI 1043220825
$5,080.37
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $580 · 2021: $740 · 2022: $1,193 · 2023: $553 · 2024: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.36 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,944.75 | 2019-2024 | |
| Abbvie INC. | $525.32 | 2019-2024 | |
| Glaxosmithkline, LLC. | $371.09 | 2019-2022 | |
| Amgen INC. | $337.06 | 2019-2024 | Tavneos, Enbrel |
| Ucb, INC. | $284.72 | 2019-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.94 | 2020-2024 | Cyltezo |
| Aurinia Pharma U.S., INC. | $207.66 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $180.36 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $174.41 | 2019 | |
| Janssen Biotech, INC. | $95.81 | 2019-2024 | Tremfya |
| Celgene Corporation | $89.40 | 2019 | |
| Radius Health, INC. | $77.59 | 2019-2022 | |
| Genzyme Corporation | $61.45 | 2020-2023 | |
| Horizon Therapeutics Plc | $59.17 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $59.12 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $58.45 | 2019 | |
| Calliditas Therapeutics US INC. | $56.61 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $35.00 | 2023 | Arcalyst |
| Lilly USA, LLC | $33.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.74 | 2020 | |
| Medtronic, INC. | $25.35 | 2023 | Minimed 780g |
| Genentech USA, INC. | $24.41 | 2021 | |
| Melinta Therapeutics, LLC | $22.58 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.62 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $19.93 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.77 | 2022 | |
| Daiichi Sankyo INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.